Onbrez 150Mcg Capsules + 1 Inhaler 30S (Pack Size 3 X 10S)

Brand : novartis pharmaceuticals

Rs. 790.10

Rs. 831.70

|

QUICK DELIVERY

SPECIFICATION

Requires Prescription (YES/NO)

Yes

Generics

Indacaterol maleate

Used For

Chronic Obstructive Pulmonary Disease

How it works

Indacaterol is a long-acting beta2-adrenergic agonist for once-daily administration. When inhaled, indacaterol acts locally in the lung as a bronchodilator. Indacaterol is a nearly full agonist at the human beta2-adrenergic receptor with nanomolar potency. In isolated human bronchus, indacaterol has a rapid onset of action and a long duration of action. The pharmacological effects of beta2-adrenoceptor agonists, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. In vitro studies have shown that indacaterol has more than 24-fold greater potency at beta2- receptors compared to beta1-receptors and 20-fold greater potency compared to beta3-receptors. This selectivity profile is similar to formoterol. The clinical significance of this finding is unknown.

USAGE AND SAFETY

Dosage

Indacaterol maleate

Side Effects

RT , inflammation and congestion , diabetes , headache , dizziness , chest pain , ischaemic heart disease , cough , pharyngeo-laryngeal pain , rhinorrhoea , muscle spasm , peripheral oedema . Reports of hypersensitivity .

Drug Interactions

Sympathomimetics , beta-blockers , xanthines , steroids , diuretics .

Indication

It is used for the maintenance treatment of COPD .

When not to Use

It (indacaterol maleate) is contraindicated in patients with hypersensitivity to indacaterol maleate .

PRECAUTIONS

Precaution

When prescribing ONBREZ , the healthcare professional should also provide the patient with an inhaled, short-acting bronchodilator for treatment of COPD symptoms that occur acutely, despite regular once-daily use of ONBREZ .

WARNINGS

Warning 1

ONBREZ is only indicated for COPD. ONBREZ should not be used in asthma due to the absence of long-term safety and efficacy data in asthma with ONBREZ .

Warning 2

When beginning treatment with ONBREZ , patients who have been taking inhaled, short-acting bronchodilators on a regular basis (e.g., four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms.

Warning 3

As with other inhalation therapy, administration of ONBREZ may result in paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, ONBREZ should be discontinued immediately and alternative therapy instituted.